<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063683</url>
  </required_header>
  <id_info>
    <org_study_id>2019315</org_study_id>
    <nct_id>NCT04063683</nct_id>
  </id_info>
  <brief_title>Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.</brief_title>
  <official_title>Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma: a Single Arm, Multicentre Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of paclitaxel and DDP combined with Anlotinib in the
      treatment of advanced esophageal squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress free survival (PFS)</measure>
    <time_frame>From first treatment，each 42 or 63 days until PD or death(up to 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>each 42 or 63 days until intolerant the toxicity or PD (up to 24 months) ]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>each 42 or 63 days until intolerant the toxicity or PD (up to 24 months) ]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response(DOR)</measure>
    <time_frame>each 42 or 63 days until intolerant the toxicity or PD (up to 24 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride, Paclitaxel, cisplatin</intervention_name>
    <description>anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.
Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.
Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle.</description>
    <arm_group_label>Anlotinib with chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histopathology confirmed unresectable, locally recurrent or metastatic advanced
             esophageal squamous cell carcinoma (excluding mixed type adenosquamous carcinoma );

          -  Those who have not received systemic treatment before, or who relapsed after (new)
             adjuvant therapy/radical surgery more than 6 months ; Note: Including advanced or
             recurrent Patients who ever received only radiotherapy on non-target lesions. The
             duration from the end of palliative treatment for local lesions (non-target lesions)
             to enrollment should &gt; 2 weeks;

          -  According to RECIST 1.1, at least one measurable lesion; the measurable lesions should
             not have received local treatment such as radiotherapy (for the lesions in the area
             where received local radiotherapy, it can also be regarded as a target lesion if
             confirmed to progress according to the recist1.1);

          -  Age from 18-75 years old;

          -  ECOG PS score: 0-1; expected survival time more than 3 months;

          -  Main organs function is normal;

          -  Women of childbearing potential should agree to use and utilize an adequate method of
             contraception (such as intrauterine device，contraceptive and condom) throughout
             treatment and for at least 3 months after study is stopped；the result of serum or
             urine pregnancy test should be negative before enrollment；Man participants should
             agree to use and utilize an adequate method of contraception throughout treatment and
             for at least 2 months after study is stopped.

          -  Patients should participate in the study voluntarily and sign informed consent

        Exclusion Criteria:

          -  Patients tends to have complete obstruction or patients requiring interventional
             treatment for obstruction;

          -  ulcerated esophageal squamous cell carcinoma patients;

          -  after esophageal or endotracheal stent implantation;

          -  Patients with a high risk of bleeding or perforation due to the apparent invasion of
             adjacent organs (aorta or trachea) of the esophageal lesion, or patients who have
             formed fistulas;

          -  patients with ESCC who have not undergone surgical resection but have not reduced
             esophageal lesions after radiotherapy;

          -  allergic to paclitaxel and cisplatin preparations or excipients;

          -  Adjuvant chemotherapy patients who have used paclitaxel or cisplatin, and relapse or
             metastasize within one year;

          -  A variety of factors affecting oral medications (such as inability to swallow, chronic
             diarrhea, and intestinal obstruction);

          -  The of liver metastases accounts for more than 50% of the total liver volume;

          -  patients with any severe and / or uncontrolled disease, including:Unsatisfactory blood
             pressure control using antihypertensive drugs (systolic blood pressure ≥150 mmhg or
             diastolic blood pressure ≥100) Mmhg) patients; patients with grade ≥ myocardial
             ischemia or myocardial infarction, arrhythmia (including qt interval ≥ 480ms);
             according to nyha criteria, iii-iv cardiac dysfunction, or cardiac ultrasonography
             prompted left ventricular ejection fraction (lvef) &lt;50% of patients;live Severe
             infection that is sexual or uncontrolled;Liver diseases such as cirrhosis,
             decompensated liver disease, chronic active hepatitis;poor diabetes control (fasting
             blood glucose (fbg)&gt;10mmol/l);Urine routine indicates that urine protein ≥ ++, and
             confirmed 24-hour urine protein quantitation &gt; 1.0 g;

          -  long-term unhealed wounds or fractures;

          -  Patients with active hemorrhage within 2 months of primary lesions; pulmonary
             hemorrhage with NCI CTC AE grade &gt;1, 4 weeks before of enrollment; other sites of
             bleeding NCI CTC AE grade &gt;2, 4 weeks before of enrollment; patients with bleeding
             tendency (such as active gastrointestinal ulcers) or patients undergoing thrombolytic
             or anticoagulant therapy such as warfarin, heparin or its analogues;

          -  Have undergone major surgery (craniotomy, thoracotomy or open surgery) within 4 weeks
             prior to the first dose study or Major surgery is required during the study period.

          -  A history of gastrointestinal perforation and/or fistula occurred within 6 months
             prior to treatment; or an overactive/venous thrombosis event such as a cerebrovascular
             accident (including transient ischemic attack), deep vein thrombosis, and lung
             Embolism.

          -  Symptomatic central nervous system metastasis and/or cancerous meningitis are known to
             exist;

          -  Clinically significant ascites, including any ascites that can be found on a physical
             examination, ascites that has been treated or currently in need of treatment, and only
             those with a small amount of ascites but no symptoms can be selected;

          -  A moderate amount of fluid in both sides of the chest, or a large amount of fluid in
             one side of the chest, or has caused respiratory dysfunction Patient to be drained;

          -  known to have active tuberculosis;

          -  suffering from interstitial lung disease requiring steroid therapy;

          -  Uncontrolled metabolic disorders or other non-malignant tumors or systemic diseases or
             cancer secondary reactions that can lead to higher medical risks and/or survival
             Evaluation of uncertainty;

          -  Significantly malnourished patients;

          -  those who have a history of psychotropic substance abuse and are unable to quit or
             have a mental disorder;

          -  A history of immunodeficiency, including a positive HIV test or other acquired,
             congenital immunodeficiency disease, or a history of organ transplantation;

          -  History of other primary malignancies, but the following : 1) complete remission of
             malignant tumors for at least 2 years prior to enrollment and no additional treatment
             during the study; 2) non-melanoma skin cancer or malignant freckle-like sputum with
             adequate treatment and no evidence of disease recurrence; 3) adequately treated and In
             situ carcinoma without evidence of disease recurrence;

          -  Female patients who are pregnant or breastfeeding

          -  According to the investigator's judgment, there are serious concomitant diseases that
             endanger the safety of the patient or affect the patient's completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LUO SUXIA</last_name>
    <role>Study Chair</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>luo suxia</last_name>
    <phone>0086-18638553211</phone>
    <email>luosxrm@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ANYANG Cancer Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <zip>455000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WANG junsheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Henan University of Science and Technolog</name>
      <address>
        <city>Luoyan</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUO YANZHEN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan cancer hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LUO SUXIA</last_name>
      <phone>0086-18638553211</phone>
    </contact>
    <investigator>
      <last_name>Li ning</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>cheng yufeng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LI BAOSHENG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi Central Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZHANG DIANFU</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

